Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With (131)I-Metaiodobenzylguanidine (MIBG)

Ítems similars

• Phase I Study of Vincristine, Irinotecan, and (131)I-Metaiodobenzylguanidine ((131)I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial
  per: DuBois, Steven G., et al.
  Publicat: (2012)
• Different outcomes for relapsed vs. refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG)
  per: Zhou, Margaret J., et al.
  Publicat: (2015)
• Phase 1 Study of Vorinostat as a Radiation Sensitizer with (131)I-Metaiodobenzylguanidine ((131)I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
  per: DuBois, Steven G., et al.
  Publicat: (2015)
• Response, Survival and Toxicity after (131)I-MIBG Therapy for Neuroblastoma in Pre-Adolescents, Adolescents and Adults
  per: Polishchuk, Alexei L., et al.
  Publicat: (2011)
• Thyroid and Hepatic Function After High Dose (131)I-Metaiodobenzylguanidine ((131)I-MIBG) Therapy for Neuroblastoma
  per: Quach, Alekist, et al.
  Publicat: (2010)